First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis - Test2 - elhamkhani - TriplyDB

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

http://www.wikidata.org/entity/Q22241417

about

The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis Intranasal Administration of Interferon Beta Attenuates Neuronal Apoptosis via the JAK1/STAT3/BCL-2 Pathway in a Rat Model of Neonatal Hypoxic-Ischemic Encephalopathy The role of innate and adaptive immunity in Parkinson's disease.[Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].

P2860

Q30986945-359842A2-FFCA-4BB8-8064-CE3375F744F6 Q36407218-8D825A3F-7EB3-43CE-9D88-1DA6CDD9C1FC Q37299279-7ABF7EA9-4D12-4D1A-BCBD-F065ED6D739E Q38166155-88C7A6A3-94A7-4935-8D93-A4AA73CE77FA Q45155454-AB65C9BD-603E-47BA-9C47-D7EF9BF2C796

P2860

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

http://www.wikidata.org/entity/Q22241417

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@ast

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en-gb

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@nl

type

label

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@ast

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en-gb

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@nl

altLabel

First-line disease-modifying t ...... osis: a comprehensive overview

@en

prefLabel

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@ast

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en-gb

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@nl

P1433

Q22241417-4BA156C0-511B-41DD-9660-CA93C04AB540

P1476

Q22241417-A609B24F-99B2-48EF-9749-1FB1699FA2B8

P2093

Q22241417-B4BDD99B-DC6A-4B42-A70A-D853CFB7AF7A

Q22241417-C9FFCDC7-10D4-49E4-8BAF-3DFD50E32C1C

P2860

Q22241417-0044ADEC-E1D7-4BA4-A595-93AF4269AE5B

Q22241417-0A70523D-5D0B-4115-9B84-524A91F2CE57

Q22241417-0BC6382D-F7CA-4284-89F9-1A46EF06ED36

Q22241417-1554500B-C65C-4169-872D-A0180660164D

Q22241417-202E7A83-61C8-42A9-8C1E-DD27EFE8A000

Q22241417-20307831-DB7D-469F-9182-D372F39727A0

Q22241417-24C53BA7-B020-4DF9-8020-283C55302072

Q22241417-25233CB3-BBA9-41A2-812D-315EA4A87B7F

Q22241417-2B273C60-37A8-451C-8F12-46DC08C44908

Q22241417-34262283-43FE-4A4D-B0C4-2A96FE5F08C3

P2888

Q22241417-27BCB709-0EAC-4428-AF58-CCEC2C90029B

P304

Q22241417-3018A689-59B1-485A-865F-73ABEF3F606E

P31

Q22241417-EF1AB12E-30F5-4CC4-8E5C-3BB8A6D0ECD9

P3181

Q22241417-1451FD13-32E9-4BE1-970D-5A455BF6A80A

P356

Q22241417-521C061C-3C47-4F33-B009-4D2EF84EC894

P407

Q22241417-C124CCD5-2ABA-4DCA-A8F6-388A04290580

P433

Q22241417-089FA673-114E-4D9E-BF11-80804840C103

P478

Q22241417-C70CDB27-6002-4352-B679-33C47718D18F

P577

Q22241417-2E09A4CB-BFA2-4D8F-ACB0-60E20A7DDB0D

P6179

Q22241417-900654C1-C0B4-4683-9B70-AAE9E4B9F7B0

P698

Q22241417-50935B5E-5FDD-4DB1-9DDB-E73938EBC132

P921

Q22241417-3F791219-A067-4CEB-B85D-602C676C63F1

P3181

P356

11634010-000000000-00000

P1433

P1476

First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis

@en

P2093

Jessica Johnston

http://www.w3.org/2001/XMLSchema#string

Tsz-Yin So

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Multiple sclerosis

Interferon-beta1a for the treatment of multiple sclerosis.

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Younger children with MS have a distinct CSF inflammatory profile at disease onset

Therapeutic strategies in childhood multiple sclerosis

Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Consensus definitions proposed for pediatric multiple sclerosis and related disorders.

Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.

P2888

11634010-000000000-00000

P304

1195-1211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3298441

http://www.w3.org/2001/XMLSchema#string

P356

10.2165/11634010-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015100072

http://www.w3.org/2001/XMLSchema#string

P698

22642799

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis